Abstract:Viral infection triggers the innate antiviral response in part through activation of RIG-I, a cytoplasmic sensor of 5′-triphosphorylated and uncapped single- or double-stranded RNA, which are not found among endogenous self-RNA. RIG-I signaling depends on the function of mitochondrial antiviral signaling (MAVS) protein, an adapter that links RIG-I, and the related RNA sensor MDA5, to events leading to transcriptional activation by NF-κB and IRF3. In contrast to the cytoplasmic localization of other innate immune signaling adapters, MAVS is positioned at mitochondrial membranes 1, and to a lesser extent at peroxisomal membranes 2, by virtue of a C-terminal transmembrane domain. For unknown reasons, mitochondrial localization is necessary for MAVS to propagate RIG-I signaling 1, except when MAVS is artificially dimerized 3. MAVS-deficient mice fail to produce type I interferon in response to polyI:C stimulation and are highly susceptible to RNA virus infection, supporting an essential role for MAVS in innate antiviral immunity 4, 5. Recently, the group of Zhijian Chen developed a cell free system that reconstitutes the complete RIG-I signaling pathway from 5′-triphosphorylated RNA (5′-pppRNA) to IRF3 activation 6. Hou et al. have now used this powerful in vitro system to make the remarkable discovery that MAVS forms prion-like aggregates to propagate RIG-I signaling 7. They mixed recombinant RIG-I, mitochondria, 5′-pppRNA, ATP, and K63 ubiquitin chains (K63-Ub4), or isolated mitochondria from cells infected with Sendai virus. When they analyzed MAVS from each of these preparations, they found that MAVS formed detergent- and protease-resistant aggregates larger in size than the 26S proteasome. These aggregates formed in response to RIG-I activation, either by 5′-pppRNA and K63-Ub4, or by virus infection, and induced IRF3 activation. Using purified, recombinant MAVS lacking the transmembrane and proline-rich domains, it was shown that MAVS spontaneously formed large fiber-like polymers capable of activating IRF3 in the presence of cytosolic extracts, and remarkably, of rapidly inducing the formation of similar aggregates by endogenous MAVS on mitochondria from HEK293T cells. Mitochondria exposed to the recombinant MAVS fibers also became competent to activate IRF3. The prion-like ability of MAVS fibers to convert endogenous MAVS on the mitochondrial membrane to an aggregated form was solely dependent on the presence of the CARD domain (in both recombinant and endogenous proteins), whereas sequences C-terminal to the CARD domain (but excluding the transmembrane domain) were also necessary for IRF3 activation. Thus, Hou et al. establish an unprecedented paradigm for innate immune signaling: signal transduction by autocatalytic conformational conversion of an adapter. Examples of phenotypic regulation by prion-induced changes in protein conformation remain relatively rare. To date, prion protein (PrP), which causes the transmissible spongiform encephalopathies Creutzfeld-Jacob syndrome and bovine spongiform encephalopathy (mad cow disease), is the only known mammalian prion. Conformational changes of PrP, from a folded α-helical structure to an infectious, aggregating, β sheet-rich form, replicate through contact between the normal and prion conformers and lead to disease 8. In Aplysia, a self-perpetuating conformer of cytoplasmic polyadenylation element-binding protein 1 (CPEB) supports a type of memory known as long-term facilitation 9. By far the largest number of prions has been identified in S. cerevisiae and P. anserina. At least nine are known, most of which display multiple conformations associated with distinct, transmissible phenotypes 8. There are several parallels between the properties of MAVS and known prion proteins. Most strikingly, aggregated MAVS had the ability to convert unaffected, mitochondrially localized MAVS molecules to the aggregated form, possibly through direct physical contact although this was not formally demonstrated. In addition, recombinant MAVS formed fiber-like polymers, similar in appearance to those formed by PrP, in a CARD domain-dependent manner. MAVS polymers were also resistant to protease and detergent treatments, features common to prions. Despite these similarities, MAVS aggregates did not stain with Congo red, a dye commonly used to label β sheet-rich, insoluble aggregates called amyloids and formed by most prions. Consistent with this finding, the MAVS CARD domain appears to lack amyloid prion-forming domains that are enriched for polar glutamine and/or asparagine residues. Glutamines (and asparagines) are thought to hydrogen bond with each other to hold parallel amyloid β sheets together, and to direct new monomers joining the amyloid filament to assume the same conformation as the previous molecules (i.e., replication) 10. The three dimensional atomic structure of MAVS aggregates may prove to be non-amyloid; non-amyloid prions are known to exist 11 but their mechanisms of replication are much less well characterized. Understanding how MAVS aggregates mediate RIG-I signaling will require answering how MAVS aggregation is initiated and how it is resolved in vivo. MAVS fiber formation in cells has not been observed, and may provide insight into the mechanism by which the prion-like conformation of MAVS differs from the inactive conformation, and how nucleation at the mitochondrial membrane occurs. Notably, a recent study demonstrated that the plasma membrane is the initial site of conversion of cellular PrP to the prion form 12, raising the possibility that MAVS conversion to the activated prion-like form also requires membrane association, in this case with mitochondria. Questions also remain regarding the role of MAVS-RIG-I interaction in the MAVS activation/aggregation process. One possible scenario is that physical interaction with activated RIG-I induces the conformational switch to the prion-like form of MAVS, which is subsequently propagated to other molecules of MAVS. Conversion of the cellular form of PrP (PrPC) to the prion form (PrPSc) entails binding of PrPC to an oligomer of PrPSc, a process called 'seeding'. Analogously, dimers or oligomers of RIG-I may seed the formation of MAVS prion-like aggregates (Figure 1). Generation of the first MAVS-prion template by RIG-I would ensure that MAVS activation/aggregation only occurs in response to viral infection or other RIG-I activators. Hou et al. note that the CARD domains of RIG-I and MDA5 share little sequence homology with that of MAVS, suggesting the possibility that the conformationally distinct RIG-I CARD domain could induce alterations to the MAVS CARD structure that promote the prion-like conformation. They also demonstrated that geldanamycin, an inhibitor of Hsp90, blocks the formation of MAVS aggregates, suggesting that Hsp90 may be required for assembly of the aggregates; a caveat of this finding is that the action of geldanamycin was not shown to be restricted to Hsp90. Figure 1 Hypothetical model of the switch to the prion-like form of MAVS. (A) The switch may be triggered by interactions between the non-prion CARD domain of MAVS (blue) and the CARD domains of dimers or oligomers of RIG-I (green), which induce a conformational ... The removal of MAVS aggregates is presumably required to halt signaling, and conversely, persistence of the aggregates may result in unmitigated signaling leading to autoimmunity. PCBP2 has been reported to recruit the E3 ligase AIP4 to MAVS, leading to MAVS ubiquitination and subsequent degradation by the proteasome 13. However, the degradation of MAVS aggregates by this mechanism has not been investigated. It seems unlikely that MAVS-prions are inactivated by dilution, which occurs in yeast by cell division and affects the persistence of yeast prions. Further studies on prion degradation and its regulation, about which little is known, may shed light on the mechanism of removal of MAVS aggregates. One of the most intriguing questions raised by the findings of Hou et al. is how downstream signaling is propagated by aggregates of MAVS. The signaling events downstream from MAVS, namely TRAF6 activation leading to IKK complex formation and NF-κB activation, as well as TRAF3 activation leading to TBK1-dependent IRF3 activation, are identical to those downstream from MyD88, an adapter for the Toll-like receptors (TLRs; except TLR3) and interleukin-1 and -18 receptors (IL-1R/18R). It seems plausible that the MyD88 and MAVS adapter complexes, both of which signal to TRAF6 and TRAF3, bear some structural similarity, at least at the interface with these TRAFs, that permit them to interact with and/or activate the TRAFs. Recently, the crystal structure of the signaling complex formed by the death domains (DDs) of MyD88, IRAK4, and IRAK2, termed the Myddosome, was reported 14. Like the isolated CARD domain of MAVS 15, the DD of MyD88, IRAK4, and IRAK2 folds into a six-helix bundle; six MyD88, four IRAK4, and four IRAK2 DDs are arranged in a left-handed helix in the Myddosome, triggering downstream signaling. Assembly of the Myddosome, with MyD88 molecules oligomerizing to form the initial 'seed' for complex formation, is reminiscent of the seeding of prion polymers. An interesting possibility is that, seeded by a complex of RIG-I CARD domains, the six-helix bundle CARD domain of MAVS might also form left-handed helical fibers or aggregates to activate TRAF6 and TRAF3 (Figure 1). The idea that immune signaling depends upon autocatalytic changes in protein conformation unites two very different fields and makes us wonder whether, as with prions, specific mutations of MAVS or related proteins can cause spontaneous assembly, altering the propensity to develop disease or causing it outright.

Abstract:Article7 August 2019free access Source DataTransparent process TRAF3IP3 mediates the recruitment of TRAF3 to MAVS for antiviral innate immunity Wenting Zhu orcid.org/0000-0001-5195-6107 State Key Laboratory of Molecular Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, China Search for more papers by this author Jiaxin Li State Key Laboratory of Molecular Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, China Search for more papers by this author Rui Zhang State Key Laboratory of Molecular Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, China Search for more papers by this author Yixiang Cai State Key Laboratory of Molecular Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, China Search for more papers by this author Changwan Wang State Key Laboratory of Molecular Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, China Search for more papers by this author Shishi Qi State Key Laboratory of Molecular Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, China Search for more papers by this author She Chen National Institute of Biological Sciences, Beijing, China Search for more papers by this author Xiaozhen Liang Key Laboratory of Molecular Virology and Immunology, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai, China Search for more papers by this author Nan Qi Corresponding Author [email protected] orcid.org/0000-0002-1423-7709 State Key Laboratory of Molecular Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, China Institute of Engineering Biology and Health, Collaborative Innovation Center of Yangtze River Delta Region Green Pharmaceuticals, College of Pharmaceutical Sciences, Zhejiang University of Technology, Hangzhou, Zhejiang, China Search for more papers by this author Fajian Hou Corresponding Author [email protected] orcid.org/0000-0002-5380-0613 State Key Laboratory of Molecular Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, China Search for more papers by this author Wenting Zhu orcid.org/0000-0001-5195-6107 State Key Laboratory of Molecular Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, China Search for more papers by this author Jiaxin Li State Key Laboratory of Molecular Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, China Search for more papers by this author Rui Zhang State Key Laboratory of Molecular Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, China Search for more papers by this author Yixiang Cai State Key Laboratory of Molecular Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, China Search for more papers by this author Changwan Wang State Key Laboratory of Molecular Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, China Search for more papers by this author Shishi Qi State Key Laboratory of Molecular Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, China Search for more papers by this author She Chen National Institute of Biological Sciences, Beijing, China Search for more papers by this author Xiaozhen Liang Key Laboratory of Molecular Virology and Immunology, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai, China Search for more papers by this author Nan Qi Corresponding Author [email protected] orcid.org/0000-0002-1423-7709 State Key Laboratory of Molecular Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, China Institute of Engineering Biology and Health, Collaborative Innovation Center of Yangtze River Delta Region Green Pharmaceuticals, College of Pharmaceutical Sciences, Zhejiang University of Technology, Hangzhou, Zhejiang, China Search for more papers by this author Fajian Hou Corresponding Author [email protected] orcid.org/0000-0002-5380-0613 State Key Laboratory of Molecular Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, China Search for more papers by this author Author Information Wenting Zhu1,‡, Jiaxin Li1,‡, Rui Zhang1, Yixiang Cai1, Changwan Wang1, Shishi Qi1, She Chen2, Xiaozhen Liang3, Nan Qi *,1,4 and Fajian Hou *,1 1State Key Laboratory of Molecular Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, China 2National Institute of Biological Sciences, Beijing, China 3Key Laboratory of Molecular Virology and Immunology, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai, China 4Institute of Engineering Biology and Health, Collaborative Innovation Center of Yangtze River Delta Region Green Pharmaceuticals, College of Pharmaceutical Sciences, Zhejiang University of Technology, Hangzhou, Zhejiang, China ‡These authors contributed equally to this work *Corresponding author. Tel: +86 571 88320865; Email: [email protected] *Corresponding author. Tel: +86 21 54921351; Email: [email protected] EMBO J (2019)38:e102075https://doi.org/10.15252/embj.2019102075 PDFDownload PDF of article text and main figures. Peer ReviewDownload a summary of the editorial decision process including editorial decision letters, reviewer comments and author responses to feedback. ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinked InMendeleyWechatReddit Figures & Info Abstract RIG-I-MAVS antiviral signaling represents an important pathway to stimulate interferon production and confer innate immunity to the host. Upon binding to viral RNA and Riplet-mediated polyubiquitination, RIG-I promotes prion-like aggregation and activation of MAVS. MAVS subsequently induces interferon production by activating two signaling pathways mediated by TBK1-IRF3 and IKK-NF-κB respectively. However, the mechanism underlying the activation of MAVS downstream pathways remains elusive. Here, we demonstrated that activation of TBK1-IRF3 by MAVS-Region III depends on its multimerization state and identified TRAF3IP3 as a critical regulator for the downstream signaling. In response to virus infection, TRAF3IP3 is accumulated on mitochondria and thereby facilitates the recruitment of TRAF3 to MAVS for TBK1-IRF3 activation. Traf3ip3-deficient mice demonstrated a severely compromised potential to induce interferon production and were vulnerable to RNA virus infection. Our findings uncover that TRAF3IP3 is an important regulator for RIG-I-MAVS signaling, which bridges MAVS and TRAF3 for an effective antiviral innate immune response. Synopsis TRAF3IP3 mediates TRAF3 recruitment to MAVS and promotes RIG-I-MAVS antiviral signaling to stimulate type I interferon induction and antiviral innate immunity. Multimerization of MAVS-Region III is essential for its downstream TBK1-IRF3 activation. TRAF3IP3 mediates TRAF3 recruitment to MAVS-Region III and promotes TBK1-IRF3 activation upon virus infection. TRAF3IP3 plays an important role in interferon induction and antiviral innate immunity against RNA virus infection in vivo. Introduction Innate immunity plays an important role in protecting higher organisms against pathogen infection (Palm & Medzhitov, 2009; Takeuchi & Akira, 2010). In the past two decades, distinct signaling pathways have been identified to mediate proper and efficient immune responses to virus infection (Yoneyama & Fujita, 2010; Aoshi et al, 2011; Tan et al, 2018). RIG-I, one of the RIG-I-like receptors (RLRs), senses viral RNA in the cytoplasm and triggers immune signaling through its downstream adaptor protein MAVS (also known as VISA, IPS1, Cardif; Yoneyama et al, 2004; Kawai et al, 2005; Meylan et al, 2005; Seth et al, 2005; Xu et al, 2005; Chow et al, 2018; Loo et al, 2008), while cyclic GMP–AMP synthase (cGAS) detects viral DNA in the cytoplasm and launches immune response through the adaptor protein STING (also known as MITA, ERIS, MYPS; Chen et al, 2016). RIG-I-MAVS transduces antiviral signal to downstream kinases, including TBK1/IKKε and IKKα/β, which further activate transcriptional factors IRF3/IRF7 and NF-κB, respectively, to stimulate the expression of type I interferon (IFN) and proinflammatory cytokines (tenOever et al, 2004). Type I IFN (α and β) induces the expression of hundreds of interferon-stimulated genes (ISGs) and eventually an antiviral state to provide innate immunity for host cells. Upon detection of viral RNA, RIG-I switches from a “closed” conformation to an “open” one, thereby activating MAVS by inducing its prion-like aggregation (Hou et al, 2011; Kowalinski et al, 2011; Luo et al, 2011; Cai et al, 2014; Peisley et al, 2014; Wu et al, 2014). It has been shown recently that Riplet-mediated ubiquitination is crucial for RIG-I-mediated MAVS activation and the signal transduction from RIG-I to MAVS could be elegantly reconstituted in vitro using purified components (Zeng et al, 2010; Shi et al, 2017). In contrast to such an elaborate understanding of the MAVS upstream signaling pathway, its downstream signaling has been unclear. MAVS contains multiple tumor necrosis factor receptor-associated factor (TRAF)-binding sites for TRAF proteins, including TRAF2, TRAF3, TRAF5, and TRAF6, which play redundant roles in mediating MAVS downstream signaling (Seth et al, 2005; Xu et al, 2005; Pineda et al, 2007; Liu et al, 2013; Fang et al, 2017). The identification of Ubc5 as an essential player for MAVS downstream signaling indicated the involvement of a ubiquitination event and supported the role of the TRAF proteins, which are E3 ubiquitin ligases (Zeng et al, 2009). In addition, other molecules, including TRADD and TANK, were also indicated in MAVS downstream signaling (Guo & Cheng, 2007; Michallet et al, 2008). A recent report refined two previously identified TRAF-binding sites of MAVS as Regions I and II, which contribute to IKK-NF-κB activation, and further uncovered MAVS-Region III as a novel site responsible for TBK1-IRF3 activation (Shi et al, 2015). Phosphorylation of MAVS at a site located in its Region III was demonstrated to be critical for TBK1-IRF3 activation (Liu et al, 2015). However, how MAVS-Region III recruits and activates its downstream signaling molecules such as TRAFs is largely unknown. The recruitment of TRAF3 to MAVS is an essential step in RIG-I-MAVS antiviral signaling (Saha et al, 2006; Paz et al, 2011; Belgnaoui et al, 2012). However, the mechanism of TRAF3 recruitment by MAVS remains unknown. Interestingly, TRAF3 interacting protein 3 (TRAF3IP3), also known as TRAF3-interacting JNK-activating modulator (T3JAM), has been reported to associate with TRAF3 and express at high levels in a variety of immune organs (Zou et al, 2015; Yu et al, 2018). Previous studies indicated that TRAF3IP3 and TRAF3 synergistically promote JNK but not NF-κB activation, and TRAF3IP3-mediated ERK signaling is critical in thymocyte development (Dadgostar et al, 2003). TRAF3IP3 also promotes autophagy and thus plays an important role in marginal zone B-cell development and survival (Peng et al, 2015). Nevertheless, how TRAF3IP3 might contribute to antiviral innate immune signaling and whether it might be involved in RIG-I-MAVS pathway have not been explored. Prion-like aggregation of MAVS is required for its activation and presumably releases its autoinhibition on Region III after virus infection (Shi et al, 2015). Activated MAVS-Region III promotes its downstream TBK1-IRF3 activation, which is central to RIG-I signaling. To gain mechanistical insight into how MAVS activates TBK1-IRF3 signaling, we expressed MAVS-Region III in vitro and in cells and found that it becomes active after multimerization. We then identified TRAF3IP3 by affinity purification as a binding partner to multimerized active MAVS-Region III. We further found that TRAF3IP3 is accumulated on the mitochondria and mediates TRAF3 recruitment to MAVS upon virus infection. Remarkably, TRAF3IP3 plays a specific role in regulating TBK1-IRF3 but not IKK-NF-κB activation upon RNA virus infection. Traf3ip3-deficient mice showed attenuated interferon response and thus severely crippled innate immunity to RNA virus infection. Therefore, our data identify TRAF3IP3 as a critical regulator in MAVS-mediated TBK1-IRF3 activation for type I interferon production against RNA virus infection. Results The activity of MAVS-Region III depends on its multimerization state Upon virus infection, MAVS N-terminal CARD domain goes through a prion-like aggregation to release the autoinhibitory effect on Region III by its adjacent regions, which is essential for MAVS to activate downstream signaling (Shi et al, 2015). MAVS-Region III (aa-401–450) can specifically activate the TBK1-IRF3 but not IKK-NF-κB signaling (Shi et al, 2015). To investigate the mechanisms that govern Region III in MAVS signaling, we first determined whether the activity of Region III depends on its multimerization state per se. MAVS-Region III was fused with various GCN4-derived peptides, which are composed of about 31–32 amino acids and differ from each other by a few amino acids (Fig 1A). These GCN4-derived peptides were designed to form stable dimer, trimer, and tetramer, respectively (Harbury et al, 1993). Fusion proteins of MAVS-Region III were expressed in bacteria and purified to be homogeneity. These proteins demonstrated the same mobility pattern on SDS–PAGE, consistent with their similar molecular weights (Fig EV1A). In contrast, they showed differential shifting mobility on native gel electrophoresis, indicating that they have distinct multimerization states as designed (Fig EV1B). Figure 1. TRAF3IP3 associates with active MAVS-Region III Diagram for three constructs expressing MAVS-Region III C terminally tagged with GCN4-derived peptides, whose sequences are presented in bold. Recombinant MAVS-Region III-dimer (lanes 1–4), trimer (lanes 5–8), or tetramer (lanes 9–12) were subjected to IRF3 dimerization assay, respectively, in vitro. Increasing doses of recombinant MAVS-Region III were used and are shown in Fig EV1C. Immunoblotting analysis was performed following native-PAGE for the reaction mixture. pcDNA3-based constructs expressing MAVS-Region III-dimer, trimer, and tetramer were transfected into HEK293T cells, respectively. ISG54 induction was measured 36 h after transfection by quantitative PCR (qPCR). Expression levels of MAVS-Region III are shown in Fig EV1D. Recombinant MAVS-Region III-dimer or tetramer was immunoprecipitated with anti-FLAG M2 beads with or without a preincubation with S100 from HEK293T cells following an experimental procedure outlined in Fig EV1G. The IP products were resolved in SDS–PAGE, and a specific protein band pulled down with MAVS-Region III-tetramer is indicated by an arrow. TRAF3IP3 was identified in the specific band by mass spectrometry. Protein samples as described in (D) were subjected to immunoblotting analysis. The TRAF3IP3 band is indicated by an arrow and the asterisk indicated nonspecific bands. pcDNA3-FLAG-TRAF3IP3 (full-length and truncated forms) and pcDNA3-HA-MAVS were transfected into HEK293T cells, which were harvested 36 h post-transfection. Co-IP experiments were performed with anti-HA antibody, followed by immunoblotting. A diagram depicting various TRAF3IP3 deletions used in the co-IP experiments is shown in Fig EV1H. Human cells, including THP1, HeLa, HEK293, HEK293T as well as Traf3ip3−/− HEK293T, were lysed and subjected to immunoblotting to examine TRAF3IP3 expression. Data information: These data are presented as the mean values based on three independent experiments, and error bars indicate standard deviation. P values were determined by two-tailed Student's t-test. ***P < 0.001. Source data are available online for this figure. Source Data for Figure 1 [embj2019102075-sup-0004-SDataFig1.pdf] Download figure Download PowerPoint Click here to expand this figure. Figure EV1. TRAF3IP3 binds to multimerized and active MAVS-Region III (related to Fig 1) Recombinant MAVS-Region III-dimer, trimer, or tetramer was expressed in E. coli and purified as described in methods. Proteins were separated by SDS–PAGE and visualized by Coomassie blue staining. Recombinant MAVS-Region III-dimer, trimer, or tetramer was separated by native-PAGE and visualized by Commassie blue staining. SDS–PAGE and Coomassie blue staining of recombinant MAVS-Region III-dimer, trimer, or tetramer-FLAG as described in Fig 1B. Immunoblotting analysis indicates expression levels of pcDNA3-MAVS-Region III-dimer, trimer, or tetramer-FLAG as described in Fig 1C. Increasing amounts of pcDNA3-MAVS-Region III-dimer, trimer, and tetramer were transfected into HEK293T cells, respectively, and IRF3 dimerizations were examined by Western immunoblotting. pcDNA3-based constructs expressing MAVS-Region III-dimer, trimer, and tetramer were transfected into HEK293T cells, respectively. IL6 induction was measured 36 h after transfection by qPCR. All data are presented as the mean values based on three independent experiments, and error bars indicate s.d. P values were determined by unpaired two-tailed Student's t-test. NS indicates no statistically significant difference. A cell-free system for identification of MAVS-interacting factors facilitate downstream IRF3 activation. In vitro assay was initiated by incubation of HEK293T cell S100 fractions with recombinant MAVS-Region III-dimer or tetramer under the reaction buffer. One portion of the reaction mixture was subjected to native-PAGE for detecting (IRF3)2, while the others were incubated with anti-FLAG M2 beads. Subsequently, FLAG-tagged MAVS-(Region III) and MAVS-(Region III-L439A), as well as their associated proteins, were captured by M2 beads and eluted with FLAG peptides. A diagram illustrating domain architectures of wild-type and mutant TRAF3IP3 as described in Fig 1F. Download figure Download PowerPoint The recombinant MAVS-Region III was subjected to an activity assay in vitro, in which IRF3 dimerization was examined to monitor TBK1-IRF3 activation. As shown in Fig 1B, while MAVS-Region III-dimer could not trigger IRF3 dimerization, MAVS-Region III-tetramer was highly potent in stimulating IRF3 dimerization. These results indicate that a higher-order multimerization state is indispensable for the activity of MAVS-Region III. Moreover, we expressed various forms of MAVS-Region III in cells and examined ISG54 and IL6 induction, as indicators for TBK1-IRF3 and IKK-NF-κB activation, respectively. Consistent with the results above, MAVS-Region III-tetramer but not Region III-dimer induced the expression of ISG54 dramatically in Mavs knockout HEK293T cells (Fig 1C). IRF3 dimerization could be readily detected in cells expressing MAVS-Region III-tetramer (Fig EV1E). On the other hand, MAVS-Region III-tetramer did not induce the expression of IL6, confirming our previous findings that Region III can only activate TBK1-IRF3 but not IKK-NF-κB (Shi et al, 2015; Fig EV1F). These data suggested that high-order multimerization of MAVS-Region III is a prerequisite for its activation and function in RIG-I-MAVS signaling. TRAF3IP3 binds to multimerized and active MAVS-Region III We next used MAVS-Region III-tetramer as a bait to identify its binding partners involved in MAVS downstream signaling. Recombinant MAVS-Region III-tetramer or -dimer were preincubated with lysates from HEK293T cells and subsequently pulled down with anti-FLAG M2 beads (Fig EV1G). In the products coimmunoprecipitated with MAVS-Region III-tetramer, a specific protein band with an apparent molecular weight of ~60 k Dalton was revealed by silver staining following SDS–PAGE (Fig 1D). This band was further identified by mass spectrometry as TRAF3IP3, a TRAF3-binding protein that was previously known to be involved in multiple adaptive immune signaling (Table EV1). Immunoblotting analysis confirmed the presence of TRAF3IP3 in the pulled-down products by MAVS-Region III-tetramer (Fig 1E). Strikingly, TRAF3IP3 was not coimmunoprecipitated with MAVS-Region III-dimer or MAVS-Region III-tetramer without preincubation in vitro, suggesting that TRAF3IP3 was recruited to the active MAVS-Region III-tetramer during the preincubation process. In support of these data, the association of TRAF3IP3 with full-length MAVS was revealed in the co-immunoprecipitation assay following transient expression of both proteins in HEK293T cells (Fig 1F). Protein structural predictions indicate that the C-terminal region (residues 491–507) of TRAF3IP3 constitutes a transmembrane helix domain (TM). Our results showed that the TM domain of TRAF3IP3 was critical for its interaction with MAVS (Fig 1F). Additionally, we examined a panel of human cells and observed a broad spectrum of endogenous TRAF3IP3 expression (Fig 1G), in contrast to previous reports indicating that mouse TRAF3IP3 expression is limited to immune organs and tissues (Zou et al, 2015). TRAF3IP3 regulates IFN response to virus infection in human cells To investigate the role of TRAF3IP3 in MAVS signaling, we used small interfering RNA to downregulate TRAF3IP3 expression and analyzed the effects on virus-stimulated IFNβ induction (Figs 2A). When TRAF3IP3 was knocked down in HEK293 cells, IFNβ production in response to Sendai virus (SeV) infection was reduced to an extent that was correlated with the knockdown efficiency (Fig 2B). Similarly, IFNB induction in response to vesicular stomatitis virus (VSV) infection or poly(I:C) treatment was also greatly attenuated when TRAF3IP3 was knocked down (Fig 2C). In contrast, IFNB induction by a DNA virus (herpes simplex virus, HSV-1) in HEK293 cells was not affected by reduced expression of TRAF3IP3. These data together demonstrated that TRAF3IP3 is specifically involved in RNA virus-triggered IFNβ induction. Figure 2. TRAF3IP3 regulates interferon production in response to RNA virus infection Three pairs of small interfering RNA against TRAF3IP3 were transfected into HEK293T cells, respectively, and immunoblotting was then employed to examine the knockdown efficiency. A pair of scrambled RNA oligos was transfected and signified as con. Three pairs of si-TRAF3IP3 together with IFNβ-luciferase reporter were transfected into HEK 293T cells. Twenty-four hours after transfection, the cells were infected with (SeV) or without (mock) Sendai virus, which were harvested 6 h post-infection to measure the luciferase activity. Si-TRAF3IP3 (oligo #1) was transfected into HEK 293 cells, which were then treated with mock, VSV, SeV, poly(I:C), or HSV-1. After various treatments, IFNB inductions were measured by qPCR. Immunoblotting to detect TRAF3IP3 in wild-type and Traf3ip3−/− HEK293T cells. Wild-type and Traf3ip3−/− HEK293T cells were treated with or without VSV, SeV, or poly (I:C) as indicated for 12 h. IFNB induction was measured by qPCR. Wild-type and Traf3ip3−/− HEK293T cells were infected with GFP-VSV. Fluorescent images were taken to examine GFP-VSV proliferation at 8 h post-infection (left). Scale bar represents 10 micrometers. GFP-VSV titers were quantitated by plaque assay (right). Various expression constructs were transfected into WT and Traf3ip3−/− HEK293T cells. Thirty-six hours after transfection, IFNB induction was measured by qPCR. Protein expression levels are shown in Fig EV2A. Mavs−/− HEK293T cells were transfected with empty vector, pcDNA-FLAG-MAVS, pcDNA-FLAG-MAVS-(Region III only), or pcDNA-FLAG-MAVS-(ΔRegion III), together with pcDNA3-FLAG-TRAF3IP3 or not as indicated. Twenty-four hours after transfection, cells were infected with SeV for 12 h. IFNB induction was measured by qPCR. Protein expression levels are shown in Fig EV2B. Data information: All data are presented as the mean values based on three independent experiments, and error bars indicate s.d. P values were determined by unpaired two-tailed Student's t-test. *P < 0.05 and **P < 0.01. NS indicates no statistically significant difference. Source data are available online for this figure. Source Data for Figure 2 [embj2019102075-sup-0005-SDataFig2.pdf] Download figure Download PowerPoint Click here to expand this figure. Figure EV2. Expression levels of overexpressed proteins as indicated in Fig 2G and H (related to Fig 2) Immunoblotting to show the expression levels of FLAG-RIG-I(N), FLAG-MAVS, FLAG-TBK1, and FLAG-IRF3 S396D as indicated in Fig 2G. Immunoblotting to show the expression levels of pcDNA-FLAG-MAVS, pcDNA-FLAG-MAVS-(Region III only), pcDNA-FLAG-MAVS-(ΔRegion III), or pcDNA3-FLAG-TRAF3IP3 as indicated in Fig 2H. Download figure Download PowerPoint We then made Traf3ip3-deficient HEK293T cells by CRISPR Cas9-mediated gene editing (Fig 2D). Consistent with the data above, IFNB production in response to infections by VSV or SeV and treatment with poly(I:C) was markedly impaired in Traf3ip3−/− cells (Fig 2E). As a result, Traf3ip3−/− cells showed compromised antiviral immunity and were more permissible to VSV proliferation than wild-type cells (Fig 2F). To dissect the mechanism by which TRAF3IP3 regulates the RIG-I-MAVS pathway, we compared IFN induction in HEK293T wild type with the Traf3ip3−/− line that ectopically expressed RIG-I, MAVS or TBK1. We found that Traf3ip3 deficiency crippled RIG-I- and MAVS-triggered IFNB production (Fig 2G). In contrast, TBK1- or IRF3 (S396D)-triggered IFNB induction was not affected in Traf3ip3-deficient cells (Fig 2G). Collectively, these results showed that TRAF3IP3 plays a critical role downstream of MAVS and upstream of TBK1 in RIG-I-mediated antiviral signaling. We then examined whether TRAF3IP3 could trigger downstream signaling and IFNs production independently of MAVS by using two MAVS mutants, i.e., MAVS-Region III and MAVS-(ΔRegion III). It is known that MAVS downstream signaling bifurcates into two pathways that involve TBK1-IRF3 and IKK-NF-κB, respectively. MAVS-Region III can only activate the TBK1-IRF3 pathway, while MAVS-(ΔRegion III) can solely stimulate the IKK-NF-κB pathway. As expected, IFNB production was induced upon SeV infection in the presence of full-length MAVS, which was enhanced dramatically by transient expression of TRAF3IP3 (Fig 2H). In contrast, neither MAVS-Region III nor MAVS-(ΔRegion III) alone could induce IFNB expression upon virus infection. Ectopic co-expression of TRAF3IP3 could not restore IFNB induction in cells expressing either MAVS-Region III or MAVS-(ΔRegion III) (Fig 2H). These data demonstrated that TRAF3IP3 promotes IFN induction in a MAVS-dependent manner. TRAF3IP3 is involved in TBK1-IRF3 activation downstream of MAVS We then found that ISG54 but not IL6 induction was severely attenuated upon SeV infection in cells with TRAF3IP3 knocked down (Fig EV3A and B). This result suggested that TRAF3IP3 is required for TBK1-IRF3 activation but not IKK-NF-κB activation in virus-triggered IFNB induction. Indeed, the depletion of TRAF3IP3 dampened ISG54 induction pronouncedly upon VSV infection or poly(I:C) treatment (Fig 3A left). In contrast, depletion of TRAF3IP3 conferred marginal effect on IL6 induction under the same stimulations (Fig 3A right), suggesting that TRAF3IP3 might not be involved in IKK-NF-κB activation. As expected, the depletion of TRAF3IP3 showed little effect on either TBK1-IRF3 or IKK-NF-κB activation upon HSV-1 infection, confirming that TRAF3IP3 is not involved in DNA virus-triggered IFNβ signaling (Fig 3A). In support of these data, we found that IRF3 dimerization was inhibited dramatically in response to RNA virus infection when TRAF3IP3 was knocked down, further demonstrating that IRF3 activation was impaired in the absence of TRAF3IP3 (Fig 3B). Consistently, IS

MAVS Forms Functional Prion-like Aggregates to Activate and Propagate Antiviral Innate Immune Response

MAVS O-GlcNAcylation is Essential for Host Antiviral Immunity Against Lethal RNA Viruses.

Prion-like Behavior of MAVS in RIG-I Signaling

Virus Infection Triggers MAVS Polymers of Distinct Molecular Weight

Multiple truncated isoforms of MAVS prevent its spontaneous aggregation in antiviral innate immune signalling

Regulation of MAVS activation through post-translational modifications

Identification and characterization of MAVS, a mitochondrial antiviral signaling protein that activates NF-kappaB and IRF 3

TRAF 3 IP 3 Mediates the Recruitment of TRAF 3 to MAVS for Antiviral Innate Immunity

Identification and Characterization of MAVS, a Mitochondrial Antiviral Signaling Protein that Activates NF-κB and IRF3

Palmitoylation acts as a checkpoint for MAVS aggregation to promote antiviral innate immune responses

MAVS: A Two-Sided CARD Mediating Antiviral Innate Immune Signaling and Regulating Immune Homeostasis

MAVS Cys508 palmitoylation promotes its aggregation on the mitochondrial outer membrane and antiviral innate immunity

Ube2D3 and Ube2N are essential for RIG-I-mediated MAVS aggregation in antiviral innate immunity

MAVS-loaded unanchored Lys63-linked polyubiquitin chains activate the RIG-I-MAVS signaling cascade

Regulation of MAVS Expression and Signaling Function in the Antiviral Innate Immune Response

MAVS ubiquitination by the E3 ligase TRIM25 and degradation by the proteasome is involved in type I interferon production after activation of the antiviral RIG-I-like receptors

MicroRNA-33/33* Inhibit the Activation of MAVS Through AMPK in Antiviral Innate Immunity

Upstream ORFs Prevent MAVS Spontaneous Aggregation and Regulate Innate Immune Homeostasis

Prion-like Polymerization Underlies Signal Transduction in Antiviral Immune Defense and Inflammasome Activation

PPM1A Silences Cytosolic RNA Sensing and Antiviral Defense Through Direct Dephosphorylation of MAVS and TBK1.

The protein arginine methyltransferase PRMT9 attenuates MAVS activation through arginine methylation